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Abstract 
Introduction: Osteonecrosis of the jaw (MRONJ) linked to bisphosphonate treatment has specific characteristics 
that render its therapeutic management challenging for clinicians. Poor response to standard treatment makes it 
essential to take special precautions when treating this type of disease; therefore, antibiotic prophylaxis and/or 
antibiotic therapy have been proposed as effective and helpful tools in these situations.
Objectives: This article seeks to assess published evidence in order to evaluate the different protocols used for anti-
biotic prophylaxis and/or antibiotic therapy in the general context of patients treated with bisphosphonates.
Material and Methods: A literature review of the last 10 years was carried out in PubMed using the following 
keywords: “antibiotic prophylaxis and osteonecrosis,” “bisphosphonates AND osteonecrosis AND dental manage-
ment,” “bisphosphonate AND osteonecrosis AND antibiotic prophylaxis AND oral surgery.” A total of 188 articles 
were obtained, of which 18 were ultimately selected.
Results and Discussion: In patients treated with oral and intravenous bisphosphonates without chemotherapy-as-
sociated osteonecrosis of the jaw, antibiotic prophylaxis prior to oral surgery is an important tool to avoid osteo-
necrosis and promote healing of the affected area. If the patient previously exhibited chemotherapy-associated 
osteonecrosis after tooth extraction, antibiotic prophylaxis is indicated to prevent recurrent osteonecrosis and pro-
mote healing of the extraction site. If chemotherapy-associated osteonecrosis is already present, antibiotic therapy 
is a vital part of conservative management to reduce the symptomatology of MRONJ and keep it from worsening. 
Finally, a lack of clinical data and randomized controlled trials makes it difficult to choose the most appropriate 
protocol for the various clinical situations studied.
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Introduction
Antibiotic prophylaxis is used in dentistry to prevent in-
fections in high-risk cases, such as during surgical pro-
cedures that enable pathogens to enter the body, or in 
patients whose general health characteristics or specific 
medical condition make them more susceptible to con-
tracting new infections (1-5).
Consequently, prophylaxis is used to promote appro-
priate bioavailability of an antibiotic that can effectively 
tackle microorganisms and therefore prevent their pro-
liferation and any subsequent infections. This concept 
is the opposite of antibiotic therapy, which is prescribed 
in cases of already established infection and is aimed at 
treating symptoms rather than preventing them (6).
Antibiotic prophylaxis and/or antibiotic therapy proto-
cols have been established as an effective therapeutic 
tool in the prevention or conservative management of 
certain diseases. One such disease is chemotherapy-as-
sociated osteonecrosis of the jaw caused by bisphospho-
nates (or other drugs), described by Marx in 2003 (7) as 
an exposure of necrotic bone with more than eight wee-
ks of evolution, associated with bisphosphonates and no 
prior radiation therapy. These lesions can progress and 
become infected or even suffer other complications, ma-
king them difficult to manage and with a wide range of 
therapies providing inconsistent results (8-10).
A distinction should be made between oral and intra-
venous routes of administration of bisphosphonates 
(11,12). Intravenous bisphosphonates are indicated for 
cancer patients (pamidronate and zoledronic acid); these 
are the most potent and are more likely to result in onset 
of MRONJ. They increase sevenfold the appearance of 
MRONJ after performing dental surgery, in comparison 
with oral bisphosphonates. In addition, it should be no-
ted that the longer a treatment, the higher the risk of de-
veloping MRONJ, and larger doses also increase the risk 
of MRONJ. Intravenous bisphosphonates can remain in 
the blood for up to 10 years.
The onset of bisphosphonate-related MRONJ has also 
been correlated with different local factors (extractions, 
implant placement, periodontal disease, etc.) and sys-
temic factors (endocrine disruptions, tobacco, alcohol, 
race, age, sex, etc.) (13,14).
In view of these risk factors, patient medical history, and 
the oral-systemic regions affected by bisphosphonates 
(including suppressed bone remodeling, deterioration 
of angiogenesis, toxicity of the soft tissues, modulatory 
dysfunction of the immune system, and delayed healing), 
there are many reasons to use antibiotic prophylaxis in pa-
tients treated with oral or intravenous bisphosphonates.
On the other hand, patients treated with oral or intra-
venous bisphosphonates who have already developed 
chemotherapy-associated osteonecrosis of the jaw may 
also benefit from antibiotic therapies to avoid potentially 
serious infection that can worsen symptoms; thus, anti-
biotic therapy can help improve overall clinical condi-
tion (15-17).
The present article seeks to identify the different publis-
hed protocols of antibiotic prophylaxis and/or antibio-
tic therapy in patients treated with oral or intravenous 
bisphosphonates. To this end, a systematic review of 
the literature was carried out focusing on three clinical 
situations: a) patients treated with oral or intravenous 
bisphosphonates and without MRONJ who will undergo 
a dental extraction, b) patients treated with oral or intra-
venous bisphosphonates and with previous incidence of 
MRONJ who will undergo a dental extraction; and c) 
patients treated with oral or intravenous bisphosphona-
tes and with MRONJ, as part of their conservative ma-
nagement.
Material and Methods
A review of the literature published in PubMed over 
the last 10 years was carried out using the following 
keywords: “antibiotic prophylaxis and osteonecrosis,” 
“bisphosphonates AND osteonecrosis AND dental ma-
nagement,” “bisphosphonate AND osteonecrosis AND 
antibiotic prophylaxis AND oral surgery.” The results 
returned 29, 129, and 13 articles, respectively. The in-
clusion and exclusion criteria were then applied in order 
to fulfill the two proposed objectives.
The inclusion criteria for the first proposed objective 
(antibiotic prophylaxis protocols) were: academic publi-
cations written in English that involved reviews of the li-
terature, clinical trials, case control studies, cohorts stu-
dies and case series centered on antibiotic prophylaxis 
(indicating the antibiotic used, doses, time, and dosage 
used for treatment) in patients treated with oral or intra-
venous bisphosphonates, with or without antecedents of 
developing chemotherapy-associated osteonecrosis of 
the jaw, who were undergoing oral surgery.
The inclusion criteria for the second proposed objective 
(antibiotic treatment guidelines) were: academic publi-
cations written in English that involved reviews of the 
literature, clinical trials, or case series that specify the 
type of antibiotic used, doses and length of treatment, 
and guidelines used for antibiotic therapy in patients 
treated with oral and intravenous bisphosphonates with 
MRONJ, as part of their conservative management (the-
refore, antibiotics are used as part of patient treatment).
The exclusion criteria for both proposed objectives 
were: articles that did not meet the eligibility require-
ments for both proposed objectives, articles unrelated to 
the research topic, articles that did not have an abstract 
or with an anonymous author, letters to the editor, and 
expert opinions.
The selection process was finished by manually sear-
ching through all the bibliographic references of the se-
lected articles.
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Results
The initial search in PubMed yielded 171 results, with 
an additional 17 articles identified during the manual 
search of the collected articles’ bibliographic references. 
The flow chart seen in figure 1 details how the eligibility 
criteria were applied. A total of 18 articles were selected 
for final inclusion in the present study.
Results taken from the different articles can be seen in 
tables 1 to 3. Table 1 shows the antibiotic prophylaxis 
protocols applied to patients without previous MRONJ 
receiving treatment with oral bisphosphonates. The table 
also provides information on the antibiotic prophylaxis 
protocols used in patients without previous MRONJ 
receiving treatment with intravenous bisphosphonates. 
Table 2 is centered on antibiotic prophylaxis protocols 
in patients treated with oral or intravenous bisphospho-
nates who had previously had MRONJ. Lastly, Table 3, 
table 3 continue shows the antibiotic treatment protocols 
applied within a conservative management approach for 
patients with MRONJ receiving treatment with both oral 
and intravenous bisphosphonates.
When antibiotic prophylaxis is used in patients without 
previous MRONJ who are receiving treatment with oral 
bisphosphonates (Table 1), as well as in patients trea-
ted with intravenous bisphosphonates (Table 1), the 
most frequently used antibiotics are penicillin, amoxi-
cillin, amoxicillin/clavulanic acid, metronidazole, and/
or a combination thereof. Erythromycin, clindamycin, or 
even lincomycin are prescribed if the patient is allergic 
to penicillin or amoxicillin (15).
In the same way, the most widely used antibiotics for the 
treatment of MRONJ in patients taking oral bisphospho-
nates are penicillin, amoxicillin, amoxicillin/clavulanic 
acid, metronidazole, and/or a combination thereof. 
With regard to the length of prophylactic antibiotic 
treatment prior to and following tooth extraction, there 
is no uniform approach applied in all patients receiving 
treatment with oral or intravenous bisphosphonates. 
Despite this, most authors agree that post-extraction 
treatment regimens in patients receiving oral and intra-
venous bisphosphonates should be continued until the 
surgical site has completely healed.
Fig. 1. Flow Chart.
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Author/Year/ 
Type of study 
Number of 
patients/ 
Average age
Number of and site 
of extractions 
Oral 
Bisphosphonate:
Treatment type, 
route of 
administration, 
time and number 
of patients
Causes for 
treatment with 
bisphosphonates
and number of 
patients
Guidelines for antibiotic prophylaxis
INTRAORAL BISPHOSPHONATES 
Lodi et al. 2010 (14) 
Prospective
23 patients 
Average age: 
68.2 years 
38 extractions 
Mand: 23 
Max: 5 
Both: 2 
Clodronate PO: 1 
Duration of BP: 
17.5 months 
Multiple
myeloma: 11 
Mammary Ca.: 8 
Solid tumors: 2 
Severe
osteoporosis: 2 
Amox 1g/18h x 20d 
3 days before and 17 days after 
extraction
Saia  et al. 2010 (15) 
Prospective
60 patients 
Average age: 65 
years 
185 extractions 
Mand: 103 
Max: 82 
Risedronate PO: 2 
Duration of BP: 
ND 
Metabolic bone 
diseases: 16 
Multiple
myeloma: 44 
Will be prescribed if: 
- there is no pain: 7 days after extraction 
- there is pain: 7 days before and after 
extraction
Guideline to follow: 
Amox 1 g + Clavulanic acid 8h x 3d 
-Amox + Clavu ac. 1g/12h x 4d and 
Metro 500mg 8h x 4d 
- Allergy: Linco 500mg 12h x 7d 
INTRAVENOUS BISPHOSPHONATES 
Lodi  et al. 2010 (14) 
Prospective
23 patients 
Average age: 
68.2 years 
38 extractions 
Mand: 23 
Max: 5 
Both: 2 
Zoledronate IV: 
20 
Pamidronate IV: 1 
Duration of BP: 
17.5 months 
Multiple
myeloma: 11 
Mammary Ca.: 8 
Solid tumors: 2 
Severe
osteoporosis: 2 
Amox 1g/18h x 20d 
3 days before and 17 days after 
extraction
Saia  et al. 2010 (15) 
Prospective
60 patients 
Average age: 65 
years 
185 extractions 
Mand: 103 
Max: 82 
Zoledronate IV: 
38 
Pamidronate IV: 
15 
Neridronate IV: 4 
Duration of BP: 
ND 
Metabolic bone 
diseases: 16 
Multiple
myeloma: 44 
Prescribed if: 
- there is no pain: 7 days after extraction 
- there is pain: 7 days before and after 
extraction
Guideline to follow: 
Amox 1g + Clavu ac 8h x 3d 
-Amox + Clavu ac. 1g/12h x 4d and 
Metro 500mg 8h x 4d 
- Allergy: Linco 500mg 12h x 7d 
Scoletta  et al. 2011 (16) 
Prospective
64 patients 
Average age: 
64.81 +/- 10.98 y 
220 extractions 
Mand: 113 
Max: 107 
Zoledronate IV: 
57 
Pamidronate IV: 2 
Zoled IV/Pam IV: 
5
Duration of BP: 
19.59 +/-18.95 
months 
Mammary Ca.: 32 
Multiple
myeloma: 21 
Osteoporosis: 2 
Prostate Ca.: 4 
Other diseases: 3 
Other cancers: 3 
Amox/ Clavulanate potassium 1g 8h x 
6d 
Allergy: Erythromycin 600mg 8h x 6d 
1 day before and 5 days after extraction 
Ferlito et al. 2011 (17) 
Case series 
43 patients 
Average age: 
56.4 y 
102 extractions 
Mand: 43 
Max: 59 
Zoledronate IV 
Duration of BP: 
16.2 +/- 3.2 
months 
Multiple
myeloma: 28 
Mammary Ca.: 8 
Prostate Ca.: 5 
Lung Ca.: 2 
Prophylaxis: 
Amox + Clavu ac. 1g/12 h 
2 days before and 5 days after extraction 
Kato  et al. 2013 (19) 
Retrospective
20 patients 
Average age: 
62.2 y 
62 extractions 
Mand: 36 
Max: 26 
Zoledronate IV: 
14 
Pamidronate IV: 6 
Zoled IV/Pam IV: 
1
Duration of BP: 1-
85 months 
Mammary Ca.: 11 
Multiple
myeloma: 5 
Prostate Ca.: 3 
Non-Hodgkin's 
lymphoma 1 
Amox 
-Amox + Metro 
- Clindamycin 
1 day before and 9 days after extraction 
Table 1. Antibiotic prophylaxis in patients treated with oral and intravenous bisphosphonates without previous MRONJ and who will undergo 
an extraction.
Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; 
Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: Eryth-
romycin; Clinda: Clindamycin; Peni: Penicillin.
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Author/Year/  
Type of study 
Number of 
patients/
Average age
Number of and 
site 
of extractions
Treatment 
type, route of 
administration,
time and 
number of 
patients
Causes for 
treatment with 
bisphosphonates 
and number of 
patients
Guidelines for antibiotic 
prophylaxis
INTRAVENOUS BISPHOSPHONATES 
Vescovi et al. 2015 (20) 
Prospective
36 patients 
Average age: 
68.5 y 
82 extractions 
Mand: 51 
Max: 31 
Zoledronate IV 
Duration of BP: 
9-24 months 
Multiple 
myeloma: 11 
Osteoporosis: 7 
Other cancers: 18 
Extraction prophylaxis: 
Amox 2g/d 
Management of MRONJ: 
Same treatment as before and 
Metro 1g/d 
3 days before and 2 weeks 
after extraction 
Table 2. Antibiotic prophylaxis in patients treated with oral (0 articles) or intravenous bisphosphonates without previous MRONJ and who 
will undergo an extraction.
Abbreviations: BP Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not document-
ed; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: 
Erythromycin; Clinda: Clindamycin; Peni: Penicillin.
Discussion
Antibiotic prophylaxis can be beneficial in avoiding 
the onset of MRONJ in patients who are set to undergo 
oral surgery (extraction) and are currently being treated 
with oral and intravenous bisphosphonates. If MRONJ 
has already developed and is under control, antibiotic 
treatment prophylaxis can prevent its recurrence. Mo-
reover, antibiotic prophylaxis can help reduce the symp-
toms of osteonecrosis of the jaw, aiding in a conserva-
tive management regimen. However, despite the many 
studies found in the literature, there is no consensus on 
which is the most used antibiotic and its dosage (17).
The latest consensus of the American Association of Oral 
and Maxillofacial Surgeons (AAOMS) (18) refers to the 
use of antibiotics in the systemic management of such 
patients in Stage 0 (“Systemic management, including 
use of pain medication and antibiotics”). Given that the 
same article identifies this stage as a moment in which 
there is no clinical evidence of MRONJ, this kind of si-
tuation would be the first group of study of our article. 
Aside from this indication, consensus doesn’t detail the 
most useful antibiotics or that they should be used. For 
this reason, clinical experience collected in this review 
could be useful (18).
Antibiotics used in patients without previous MRONJ 
who are receiving treatment with oral bisphosphonates, 
as well as in patients treated with intravenous bisphos-
phonates (Table 1), have already been exposed in the Re-
sults section. With regard to the length of prophylactic 
antibiotic treatment prior to and following tooth extrac-
tion, there is no uniform approach applied in all patients 
receiving treatment with oral or intravenous bisphos-
phonates. Some articles indicate that antibiotics should 
be prescribed three (14) or seven (15) days before tooth 
extraction in patients treated with oral bisphosphonates. 
Similarly, post-extraction recommendations vary, with 
articles suggesting that antibiotic prophylaxis be admi-
nistered anywhere from seven (15) to seventeen days 
(14) post-intervention. 
For patients receiving treatment with intravenous bis-
phosphonates, the articles’ recommendations for when 
to begin pre-extraction prescription of antibiotics range 
from one, (16,19) two, (17) or three days before (14) to 
seven days before extraction (15). Post-extraction anti-
biotic treatment is recommended to be started five, (16-
18) seven, (15) nine, (19) or seventeen days (14) after 
the procedure. Despite this, most authors agree that post-
extraction treatment regimens in patients receiving oral 
and intravenous bisphosphonates should be continued 
until the surgical site has completely healed.
For the above reasons, the total length of treatment time 
can vary greatly. Patients treated with oral bisphospho-
nates can receive prophylaxis for anywhere from seven 
(15) to twenty days (14). In patients treated with intra-
venous bisphosphonates, treatment time can range from 
six (16) or seven (15,17) to twenty (14) days.
Regarding the use of antibiotics for the treatment of 
MRONJ, the consensus of the AAOMS (18) identifies as 
necessary from Stage 2, indicating that the isolated mi-
croorganisms are often sensitive to penicillin. Although 
it indicates a wide variety of antibiotics used to treat 
MRONJ not identify dose or temporal patterns, which 
if addressed in this paper, can help fill that consensus. 
No articles were found on administering antibiotic pro-
phylaxis in patients receiving oral treatment with bis-
phosphonates who had also suffered previous osteone-
crosis of the jaw and were set to undergo an extraction 
in the near future. Regarding patients undergoing intra-
venous bisphosphonate treatment, only one article was 
found, in which the authors prescribe amoxicillin before 
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Author/Year/  
Type of study 
Number of 
patients/ 
Average age
Number of and site 
of extractions
Treatment type, route of 
administration, time and 
number of patients
Causes for 
treatment with 
bisphosphonates
and number of 
patients
Antibiotic treatment
ORAL BISPHOSPHONATES 
Alons et al. 2009 (21) 
Retrospective
7 patients 
Average age: 66.9 
y
7 MRONJ 
Location: Mand: 5/ Max: 
1/ Both: 1 
Stages: ND 
Clodronate PO: 1 
Combination of BP: 3 
Duration of BP: 48 months 
Multiple myeloma: 
1
Mammary Ca.: 2 
Osteoporosis: 1 
Combination of 
diseases: 1 
6 million U Penicillin G + 
1500mg Metro IV 1x a day x 1 
week
Feniticillin PO 1 x d + 1500mg 
Metro PO 1x a day x 2 weeks 
Allergy: 
1800mg Clinda IV 1x a day x 1 
week + 
1800mg Clinda PO 1x a day x 3 
weeks
Stanton  et al. 2009 (22) 
Retrospective
33 patients 
Average age: 64.5 
y
33 MRONJ 
Location: Mand: 25/ Max: 
8/ Both: 2 
Stages: ND 
Alendronate PO: 3 
Combination of BP: 4 
Duration of BP: ND 
Mammary Ca.: 18 
Multiple myeloma: 
5
Prostate Ca.: 3 
Non-Hodgkin's 
lymphoma 1 
Osteoporosis: 4 
Combination of 
diseases: 2 
Before and after surgical 
intervention: 
Levo + Metro 4 weeks until 
complete healing 
Allergy to Levo: 
Metro or Peni 
Ferlito  et al. 2012 (23) 
Case series 
94 patients 
Average age: 66 y 
94 MRONJ 
Location: ND 
Stages: Stage I: 8/ Stage II: 
86 
94 MRONJ 
Location: ND 
Stages: Stage I: 8/ Stage II: 86 
ND Pre-surgical intervention: 
Stage I: Piperacillin/Tazobactam 
IM 2g/ 12h x 5d 
Stage II: Imipenem/Cilastatin IV 
500mg 12h x 2d 
Post-surgical intervention: 
Stage I: Piperacillin/Tazobactam 
IM 2g/ 12h x 7d 
Stage II: Stage II: 
Imipenem/Cilastatin IV 500mg 
12h x 3d 
Williamson  et al. 2010 
(24) 
Prospective
40 patients 
Average age: 64 y 
40 MRONJ 
Location: Mand: 25/ Both: 
15 
Stages: Refractory 
MRONJ 
Oral Bisphosphonates: 16 
Duration of BP: ND 
Multiple myeloma: 
4
Metastasis of 
prostate ca.: 8 
Mammary Ca.: 1 
Osteoporosis: 15 
Paget 's disease: 2 
Before surgical intervention: 
Amox 1g 
After surgical intervention: Amox 
500mg 6h x 2weeks 
Allergy: Clinda 600mg before 
and after 450mg 6h x 2 weeks 
Eckardt  et al. 2011 (25) 
Case series 
142 patients 
Average age: 62 y 
142 MRONJ 
Location: Mand: 82/ Max: 
39/ Both: 21 
Stages: ND 
Ibandronate PO: 20 
Alendronate PO: 12 
Etidronate PO: 1 
Risedronate PO: 3 
Clodronate PO: 1 
Combination of BP: 2 
Duration of BP: 37.1 months 
Mammary Ca.: 51 
Prostate Ca.: 20 
Plasmacytoma: 34 
Renal Ca.: 
Lung Ca.: 8 
Other cancers: 9 
Other diseases: 2 
Pre- and post-surgical 
intervention: Peni and for 
allergies: Clinda 
Vescovi  et al. 2012 (26) 
Case series 
151 patients 
Average age: 66.6 
y
139 MRONJ 
Location: Mand: 95/ Max: 
42/ Both: 14 
Stages: Stage I: 24/ Stage 
II: 102/ Stage III: 25 
Alendronate PO: 16 
Combination of BP: 29 
Duration of BP: 48.2 months 
Multiple myeloma: 
56 
Bone metastasis: 65 
Osteoporosis: 30 
Amox PO: 1g 8h x 2 weeks 
Metro PO: 250mg 12h/ x 2 weeks 
3 days before and 10 days after 
surgical intervention 
Eckert  et al. 2007 (27) 
Case series 
24 patients 
Average age: 67 y 
24 MRONJ 
Location: Mand: 16/ Max: 
8
Stages: ND 
Alendronate PO: 3 
Ibandronate PO: 1 
Combination of BP: 9 
Duration of BP: 4-84 months 
Mammary Ca.: 9 
Multiple myeloma: 
7
Prostate Ca.: 5 
Lung Ca.: 1 
Osteoporosis: 2 
Antibiotic treatment: 
Amox + Clavu ac. 1 week 
Junquera  et al. 2009 
(28) 
Case series 
21 patients 
Average age: 65.1 
y
21 MRONJ 
Location: Mand: 17/ Max: 
4
Stages: Stage I: 7/ Stage II: 
9/ Stage III: 5 
Alendronate PO: 1 
Duration of BP: 11.2 months 
Multiple myeloma: 
5
Bone metastasis of 
Mammary Ca.: 13 
Rheumatoid arthritis 
1
Prostate Ca.: 2 
Amox 2-4g per day + Clavu ac. 
125-250mg per day x 2 weeks 
Table 3. Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.
J Clin Exp Dent. 2017;9(1):e141-9.                                                                                                                                                                        Antibiotic therapy and bisphosphonates
e147
Epstein  et al. 2010 (29) 
Case series 
6 patients 
Average age: 75 y 
6 MRONJ 
Location: ND 
Stages: ND 
Ibandronate PO: 1 
Alendronate PO: 1 
Duration of BP: ND 
Cancer patients: 4 
Osteoporosis: 2 
Pentoxifylline and alpha-
Tocopherol 
INTRAVENOUS BISPHOSPHONATES 
Eckert  et al. 2007 (27) 
Case series 
24 patients 
Average age: 67 y 
24 MRONJ 
Location: Mand: 16/ Max: 
8
Stages: ND 
Zoledronic acid IV: 9 
Pamidronate IV: 2 
Combination of BP: 9 
Duration of BP: 4-84 months 
Mammary Ca.: 9 
Multiple myeloma: 
7
Prostate Ca.: 5 
Lung Ca.: 1 
Osteoporosis: 2 
Antibiotic treatment: 
Amox + Clavu ac. 1 week 
Van De Wyngeart et al. 
2008 (30) 
Case report 
33 patients 
Average age: 58 y 
33 MRONJ 
Location: Mand: 17/ Max: 
11/ 
Both: 5 
Stages: Stage I: 9/ Stage II: 
21/ 
Stage III: 3 
Zoledronic acid IV: 21 
Pamidronate IV: 6 
Combination of BP: 27 
Duration of BP: 27 months 
Multiple myeloma: 
9
Mammary Ca.: 19 
Prostate Ca.: 3 
Renal cell Ca.: 11 
Amox + Clavu ac. 875/125mg 
Allergy: Clinda 300mg 8h x 10d 
Maintenance therapy: 
Doxi 100mg 1x a day x 3 weeks 
until complete healing 
Alons  et al. 2009 (21) 
Retrospective
7 patients 
Average age: 66.9 
y
7 MRONJ 
Location: Mand: 5/ Max: 
1/ Both: 1 
Stages: ND 
Pamidronate IV: 3 
Combination of BP: 3 
Duration of BP: 48 months 
Multiple myeloma: 
1
Mammary Ca.: 2 
Osteoporosis: 1 
Combination of 
diseases: 1 
6 million U Penicillin G + 
1500mg Metro 1x a day x 1 week 
IV 
Feniticillin 1x d + 1500mg PO + 
Metro 1x a day x 2 weeks PO 
Allergy: 
1800mg Clinda 1x a day x 1 week 
IV + 
1800mg Clinda 1x a day x 3 
weeks PO 
Saussez  et al. 2009 (31) 
Retrospective
34 patients 
Average age: 62 y 
34 MRONJ 
Location: Mand: 18/ Max 
8/ Both: 7 
Stages: Stage I: 7/ Stage II: 
22/ Stage III: 5 
Zoledronic acid IV: 21 
Pamidronate IV: 3 
Unknown: 1 
Combination of BP: 9 
Duration of BP: ND 
Bone metastasis of 
mammary Ca.: 16 
Prostate Ca.: 4 
Multiple myeloma: 
6
Other cancers: 4 
Osteoporosis: 4 
Amoxicillin or Amox/Clavu acid 
Allergy: Clinda or Doxi 
Junquera  et al. 2009 
(28) 
Case series 
21 patients 
Average age: 65.1 
y
21 MRONJ 
Location: Mand: 17/ Max: 
4
Stages: Stage I: 7/ Stage II: 
9/ Stage III: 5 
Zoledronic acid IV: 19 
Pamidronate IV: 1 
Duration of BP: 11.2 months 
Multiple myeloma: 
5
Bone metastasis of 
mammary Ca.: 13 
Rheumatoid 
arthritis: 1 
Prostate Ca.: 2 
Amox 2-4g per day + Clavu ac. 
125-250mg a day x 2 weeks 
Stanton  et al. 2009 (22) 
Retrospective
33 patients 
Average age: 64.5 
y
33 MRONJ 
Location: Mand: 25/ Max: 
8/ Both: 2 
Stages: ND 
Zoledronic acid IV: 26 
Combination of BP: 4 
Duration of BP: ND 
Mammary Ca.: 18 
Multiple myeloma: 
5
Prostate Ca.: 3 
Non-Hodgkin's 
lymphoma 1 
Osteoporosis: 4 
Combination of 
diseases: 2 
Before and after surgical 
intervention: 
Levo + Metro 4 weeks until 
complete healing 
Allergy to Levo: 
Metro or Peni 
Epstein  et al. 2010 (29) 
Case series 
6 patients 
Average age: 75 y 
6 MRONJ 
Location: ND 
Stages: ND 
Zoledronic acid IV: 2 
Pamidronate IV: 2 
Duration of BP: ND 
Cancer patients: 4 
Osteoporosis: 2 
Pentoxifylline and alpha-
Tocopherol 
Williamson  et al. 2010 
(24) 
Prospective
40 patients 
Average age: 64 y 
40 MRONJ 
Location: Mand: 25/ Both: 
15 
Stages: Refractory 
MRONJ 
Bisphosphonates IV: 24 
Duration of BP: ND 
Multiple myeloma: 
4
Metastasis of 
prostate Ca.: 8 
Mammary Ca.: 1 
Osteoporosis: 15 
Paget 's disease 2 
Before surgical intervention: 
Amox 1g 
After surgical intervention: Amox 
500mg 4x a day x 2weeks 
Allergy: Clinda 600mg before 
and after 450mg 4 a d x 2 weeks 
Eckardt  et al. 2011 (25) 
Case series 
142 patients 
Average age: 62 y 
142 MRONJ 
Location: Mand: 82/ Max: 
39/ Both: 21 
Stages: ND 
Zoledronic acid IV: 82 
Pamidronate IV: 21 
Combination of BP: 2 
Duration of BP: 37.1 months 
Mammary Ca.: 51 
Prostate Ca.: 20 
Plasmacytoma: 34 
Renal Ca.: 14 
Lung Ca.: 8 
Other cancers: 9 
Other diseases: 2 
Pre- and post-surgical 
intervention: Peni and for 
allergies: Clinda 
Table 3 (continue). Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with 
MRONJ.
the extraction and add metronidazole after the procedu-
re (20). The pharmaceutical treatment began three days 
prior to the procedure and was continued for two weeks 
afterwards (18 days in total) (20).
Long-term antibiotic treatment appears to yield better re-
sults in regard to promoting proper healing of the alveo-
lar sockets (17,20) and avoiding the onset of MRONJ. 
The most widely used antibiotics for the treatment of 
MRONJ in patients taking oral bisphosphonates are si-
milar to the used in the first group of clinical situations: 
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Hoefert  et al. 2011(32) 
Retrospective
46 patients 
Average age: 66-
83 y 
47 MRONJ 
Location: Mand: 33 / Max: 
9/
Both: 5 
Stages: Stage I: 10/ Stage 
II: 37 
Zoledronic acid IV: 20 
Pamidronate IV: 5 
Ibandronate IV: 5 
Combination of BP: 17 
Duration of BP: ND 
Multiple myeloma: 
11 
Metastasis of lung 
Ca.: 3 
Prostate Ca.: 4 
Mammary Ca.: 28 
Colon Ca.: 2 
Renal Ca.: 3 
Unknown: 6 
Two groups and different 
guidelines: 
-Group A-ST: 
Oral: Pre-surgical intervention 1-
8d 
-Group B-LT: 
Oral: Pre-intervention 23-54d 
Post-surgical intervention for 
both groups: Oral: 10-12d / IV: 7 
d
ABX used in both groups: 
Amox, Levo, Clinda, Cefaclor, 
Cefuroxime, Cipro, Cefacidin, 
Moxiflox, Doxi and Metro 
Ferlito  et al. 2012 (23) 
Case series 
94 patients 
Average age: 66 y 
94 MRONJ 
Location: ND 
Stages: Stage I: 8/ Stage II: 
86 
Zoledronic acid IV: 72 
Clodronate IM: 1 
Ibandronate IV: 1 
Neridronate IV: 4 
Duration of BP: 24 months 
ND Pre-surgical intervention: 
Stage I: Piperacillin/Tazobactam 
2g/ 12h x 5d IM 
Stage II: Imipenem/Cilastatin 
500mg 12h x 2d IV 
Post- surgical intervention: 
Stage I: Piperacillin/Tazobactam 
2g/ 12h x 7d IM 
Stage II: Stage II: 
Imipenem/Cilastatin IV: 500mg 
12h x 3d 
Vescovi  et al. 2012 (26) 151 patients 
Average age: 
139 MRONJ 
Location: Mand: 95/ Max: 
42/ Both: 14 
Stages: Stage I: 24/ 
Zoledronic acid IV: 87 
Pamidronate IV: 2 
Multiple myeloma: 
56 
Bone metastasis: 
Amox PO: 1g 3x a d x 2 weeks 
Metro PO: 250mg 2x a d x 2 
weeks
Case series 66.6 y Stage II: 102/ Stage III: 25 Combination of BP: 29 
Duration of BP: 48.2 months 
65 
Osteoporosis: 30 
3 days before and 10 days after 
surgical intervention 
Table 3 (continue-1). Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with 
MRONJ.
Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; 
Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin, Amox/Clavu ac.: Amoxicillin / Clavulanic acid, Linco: Lincomycin, Erythro: Eryth-
romycin, Clinda: Clindamycin, Peni: Penicillin; Levo: Levofloxacin; Doxi: Doxicilin; A-ST: Short-term preoperative antibiotic regime; B-LT: 
Long-term preoperative antibiotic regime.
penicillin, amoxicillin, amoxicillin/clavulanic acid, me-
tronidazole, and/or a combination thereof. There are also 
studies that prescribed penicillin G + IV metronidazole, 
(21) levofloxacin + metronidazole, (22) piperacillin + ta-
zobactam, or imipenem + cilastatin (23). If the patient is 
allergic to penicillin or amoxicillin, clindamycin is usua-
lly prescribed instead (21,24-26,30-32).
There is no consensus on total treatment time. Authors’ 
recommendations for conservative management of 
MRONJ using antibiotics include one week, (27) ten 
days, (26) fifteen days (24,26,28,29), or three or four 
weeks, until the healing process is complete (21,22). 
Most of the consulted studies agree that antibiotic 
treatment should be long-term. This is because depen-
ding on the severity of MRONJ, conservative treatment 
may be accompanied by surgical treatments with varying 
levels of invasiveness. Consequently, antibiotic therapy 
is often continued long-term until the clinical remission 
of signs and symptoms linked to MRONJ or its surgical 
treatment.
In patients treated with intravenous bisphosphonates, the 
most commonly used antibiotics are penicillin, amoxici-
llin, amoxicillin/clavulanic acid, metronidazole, and/or 
a combination thereof. Some studies also prescribed pe-
nicillin G + IV metronidazole, (21) levofloxacin + me-
tronidazole, (22) piperacillin + tazobactam, or imipenem 
+ cilastatin (23). If the patient is allergic to penicillin or 
amoxicillin, clindamycin is usually prescribed instead 
(21,24-26,30-32).
No consensus exists on total treatment times, with the 
approach being similar to treatments described for pa-
tients undergoing treatment with oral bisphosphonates. 
In any case, it is always best to carry out antibiogram 
before prescribing any antibiotics; (12) however, broad 
spectrum antibiotics can be used in cases where MRONJ 
must be treated as soon as possible.
Sparse clinical data and a lack of randomized controlled 
trials make it impossible to definitively identify the most 
appropriate protocol for each of the different clinical si-
tuations studied (33,34).
In conclusion, it is clear that in patients being treated 
with oral and intravenous bisphosphonates who have 
not had prior chemotherapy-associated osteonecrosis of 
the jaw, the use of antibiotic prophylaxis prior to oral 
surgery is an important tool in avoiding osteonecrosis 
and in promoting proper healing of the affected area. If 
a patient previously had chemotherapy-associated osteo-
necrosis after a tooth extraction, antibiotic prophylaxis 
will be indicated to prevent the recurrence of osteone-
crosis and to promote healing of the extraction site. If 
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chemotherapy-associated osteonecrosis is already pre-
sent, antibiotic therapy is a vital part of conservative 
management to reduce the symptomatology of MRONJ 
and keep it from worsening. 
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